Hit enter to search or ESC to close
Hepion PharmaceuticalsHepion Pharmaceuticals
  • About
    • Company Overview
    • Executive Team
    • Cyclophilin Expertise
    • Board of Directors
    • Scientific Advisory Board
    • Partnering
  • Liver Disease
    • Overview
    • Non-alcoholic Steatohepatitis (NASH)
    • Hepatocellular Carcinoma (HCC)
    • Viral Hepatitis
  • AI-POWR™
  • Pipeline
    • Overview
    • CRV431
    • Therapeutic Strategy
    • Clinical Trials
    • Publications
  • Newsroom
  • Investors
    • Investor Overview
    • Press Releases
    • Events
    • Presentations
    • Company Information
    • Stock Information
    • SEC Filings
    • Corporate Governance
  • Contact
    • Contact Us
    • Careers
Hepion Pharmaceuticals
Menu
  • Investor Overview
  • Press Releases
  • Events
  • Presentations
  • Company Information
  • Stock Information
  • SEC Filings
  • Corporate Governance

SEC Filings

Get Important News and Updates by Email Subscribe

© 2020 Hepion Pharmaceuticals | Disclaimer & Terms of Use | WDDI

  • About
    • Company Overview
    • Executive Team
    • Cyclophilin Expertise
    • Board of Directors
    • Scientific Advisory Board
    • Partnering
  • Liver Disease
    • Overview
    • Non-alcoholic Steatohepatitis (NASH)
    • Hepatocellular Carcinoma (HCC)
    • Viral Hepatitis
  • AI-POWR™
  • Pipeline
    • Overview
    • CRV431
    • Therapeutic Strategy
    • Clinical Trials
    • Publications
  • Newsroom
  • Investors
    • Investor Overview
    • Press Releases
    • Events
    • Presentations
    • Company Information
    • Stock Information
    • SEC Filings
    • Corporate Governance
  • Contact
    • Contact Us
    • Careers